Table 4 Safety evaluation based on adverse events observed during 12-week follow-up
Contents | ADSC group (n = 11) | ERAF group (n = 13) |
|---|---|---|
Overall | 3 | 7 |
AEs | ||
 Perianal pain | 3 | 1 |
 Anal distention | 0 | 7 |
 Uroschesis | 0 | 1 |
SAEs | 0 | 0 |
Contents | ADSC group (n = 11) | ERAF group (n = 13) |
|---|---|---|
Overall | 3 | 7 |
AEs | ||
 Perianal pain | 3 | 1 |
 Anal distention | 0 | 7 |
 Uroschesis | 0 | 1 |
SAEs | 0 | 0 |
Stem Cell Research & Therapy